Premium
The effects of benazepril, a new angiotensin‐converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study
Author(s) -
Moser M,
Abraham P A,
Bennett W M,
Brachfeld N,
Goodman R P,
McKenney J M,
Hollifield J W,
Kirkendall W M,
Lasseter K C,
Leon A S,
Lunn J A,
Miller K,
Morganroth J,
Ruddy M C,
Sambhi M P,
Stein W J,
Weber M A,
Williams R L,
Zawada E T,
Desilva J,
Gourley L A,
Whalen J J
Publication year - 1991
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1991.36
Subject(s) - benazepril , hydrochlorothiazide , blood pressure , placebo , medicine , essential hypertension , angiotensin converting enzyme , adverse effect , urology , pharmacology , endocrinology , alternative medicine , pathology
Benazepril hydrochloride is a new angiotensin‐converting enzyme inhibitor. In a multicenter study, 206 patients with mild to moderate hypertension were randomized to receive benazepril at a dose of 2, 5, 10, or 20 mg, hydrochlorothiazide, 25 mg, or placebo once daily for 4 weeks. The 20 mg dosage of benazepril lowered blood pressure to a degree equal to that of 25 mg hydrochlorothiazide: −12.217.7 mm Hg and −13.4/−7.5 mm Hg, respectively. Hydrochlorothiazide proved to be more effective in black subjects. At lower dosage levels of benazepril (2, 5, and 10 mg), blood pressure reduction was not significantly different from that with placebo. In those patients who failed to achieve goal diastolic blood pressure of <90 mm Hg with monotherapy after 4 weeks, the addition of open‐label hydrochlorothiazide (25 mg/day) to benazepril, hydrochlorothiazide, or placebo produced a substantial additional decrease in blood pressure over a 2‐week period. No definite adverse effects on hématologie measurements, serum biochemistry test results, or urinalyses were noted. Subjective adverse experiences were common in all groups but except in three or possibly four instances were not considered causally related to the study drug. Clinical Pharmacology and Therapeutics (1991) 49, 322–329; doi: 10.1038/clpt.1991.36